The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Determining complete remission in patients with AML
Christopher Hourigan, DM, DPhil, FRCP, Virginia Tech FBRI Cancer Research Center, Washington, DC, discusses the complexity of determining complete remission (CR) in patients with acute myeloid leukemia (AML), emphasizing that no single test can confirm a cure. He explains the importance of integrating early indications of the most likely outcome with clinical information to guide treatment decisions. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
